AVE1642 anti-IGF1R antibody study aims to determine optimal dose and safety in multiple myeloma
Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma
Abstract
AVE1642 anti-IGF-1R antibody study aims to establish optimal dose and safety in advanced multiple myeloma patients.